New AI-based method for early detection of lung cancer

基于人工智能的肺癌早期检测新方法

• 批准号: 10069479
• 金额: $ 274.59万
• 依托单位: SIERRA MEDICAL LTD
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10069479
• 关键词: New; AI; based; method; early

Sierra Medical (SM) is developing SM-S1 - a highly innovative early-stage lung cancer (LC) detection test which combines artificial intelligence (AI) and the biochemistry of a patient's cheek cells. Our novel analytical algorithm combines infrared spectroscopy, biological/medical information, machine learning and AI to extract subtle spectral differences between healthy and diseased cells (Slide 5). Our system is non-destructive (tests can be performed on the same sample), requires only a few hundred cells and is easy-to-use by any healthcare professionals without extensive training. It could be easily conducted at home or in a Primary Care setting (GP practice or pharmacy). Our first product, SM-S1, is a LC early detection tool that uses only a cheek swab, and our latest clinical trial results are very promising, showing sensitivity of 93%. Also, our technology and software platforms are being developed to detect other diseases, such as oesophageal and colon cancers, and analyse other sample types, as biopsy tissue samples.

Sierra Medical（SM）正在开发SM-S1 -一种高度创新的早期肺癌（LC）检测测试，它结合了人工智能（AI）和患者脸颊细胞的生物化学。我们的新型分析算法结合了红外光谱、生物/医学信息、机器学习和人工智能，以提取健康和患病细胞之间的细微光谱差异（幻灯片5）。我们的系统是非破坏性的（可以对同一样本进行测试），只需要几百个细胞，并且易于由任何医疗保健专业人员使用，无需广泛的培训。它可以很容易地在家里或在初级保健环境（全科医生的做法或药房）进行。我们的第一个产品SM-S1是一种LC早期检测工具，仅使用颊拭子，我们最新的临床试验结果非常有希望，显示灵敏度为93%。此外，我们正在开发技术和软件平台，以检测其他疾病，如食管癌和结肠癌，并分析其他样本类型，如活检组织样本。